Delayed-release prednisone-a new approach to an old therapy

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 8, 2013, Pages 1097-1106

  Buttgereit, Frank ^a   Gibofsky, Allan ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Chronobiology; Glucocorticoids; Interleukin 6; Morning stiffness; Nocturnal asthma; Polymyalgia rheumatica; Prednisone; Rheumatoid arthritis

Indexed keywords

HYDROCORTISONE; INTERLEUKIN 6; METHOTREXATE; PLACEBO; PREDNISONE;

ARTHRALGIA; BRONCHITIS; DELAYED RELEASE FORMULATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EAR DISEASE; EVENING DOSAGE; HEADACHE; HUMAN; INNER EAR DISEASE; JOINT STIFFNESS; MORNING DOSAGE; NAUSEA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; THORAX PAIN; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VITAMIN SUPPLEMENTATION;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; DELAYED-ACTION PREPARATIONS; GLUCOCORTICOIDS; HUMANS; PREDNISONE; TREATMENT OUTCOME;

EID: 84877637843     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.782001     Document Type: Review

References (41)

1. Buttgereit F, Burmester G-R, Straub RH, et al. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011;63:1-9
2. Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010-14
3. Alten RHE. Clinical trials: Insufficient data on glucocorticoid use in RA trials. Nat Rev Rheumatol 2011;7:318-19
4. Andre V, le Goff B, Leux C, et al. Information on glucocorticoid therapy in the main studies of biological agents. Joint Bone Spine 2011;78:478-83
5. Buttgereit F. Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? Ann Rheum Dis 2011;70:1881-3
6. Caporali R, Cimmino MA, Montecucco C, et al. Glucocorticoid treatment of polymyalgia rheumatica. Clin Exp Rheumatol 2011;29(5 Suppl 68):S143-7
7. Charlton R. Optimal management of giant cell arteritis and polymyalgia rheumatica. Ther Clin Risk Manag 2012;8:173-9
8. Fuhlbrigge AL, Lemanske RF, Rasouliyan L, et al. Practice patterns for oral corticosteroid burst therapy in the outpatient management of acute asthma exacerbations. Allergy Asthma Proc 2012;33:82-9
9. Smolen JS, Landewe R, Breeveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
10. Pincus T, Sokka T, Castrejon I, et al. Decline of mean initial prednisone dose from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-Term effectiveness of doses less than 5 mg/day. Arthritis Care Res 2012;doi:1002/acr.21899
11. Jacobs JWG. Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis. Rheumatology 2012;51:iv3-8
12. Kirwan Jr. Combination therapy including glucocorticoids: The new gold standard for early treatment in rheumatoid arthritis? Ann Intern Med 2012;156:390-1
13. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: Arandomized trial. Ann Intern Med 2012;156:329-39
14. Cutolo M, Straub RH, Buttgereit F. Circadian rhythms of nocturnal hormones in rheumatoid arthritis: Translation from bench to bedside. Ann Rheum Dis 2008;67:905-8
15. Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: Implications for pathophysiology and therapeutic management. Arthritis Rheum 2007;56:399-408
16. Westhovens R. The importance of chronotherapeutics in the treatment of rheumatoid arthritis. Eur Musculoskeletal Rev 2010;5:9-13
17. Cutolo M, Seriolo B, Craviotto C, et al. Circadian rhythms in rheumatoid arthritis. Ann Rheum Dis 2003;62:593-6
18. Sierakowski S, Cutolo M. Morning symptoms in rheumatoid arthritis: Defining characteristic and marker of active disease. Scand J Rheumatol 2011;40(Suppl 125):1-5
19. Cutolo M, Otsa K, Aakre O, et al. Nocturnal hormones and clinical rhythms in rheumatoid arthritis. Ann NY Acad Sci 2005;1051:372-81
20. Clarke LL, Jessop DS, Hunt LP, et al. Alleviation of morning joint stiffness by low dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. Int J Clin Rheumatol 2011;6:241-9
21. Spies C, Cutolo M, Straub RH, et al. More night than day -circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J Rheumatol 2010;37:894-9
22. Arvidson NG, Gudbjornsson B, Larsson A, et al. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis 1997;56:27-31
23. Derendorf H, Ruebsamen K, Clarke L, et al. Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. J Clin Pharmacol 2012; Epub ahead of print
24. Al-Habet SMH, Rogers HJ. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. Eur J Clin Pharmacol 1989;37:423-6
25. Kirwan JR, Clarke L, Hunt LP, et al. Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. Ann NY Acad Sci 2010;1193:127-33
26. Kirwan Jr. Targeting the time of day for glucocorticoid delivery in rheumatoid arthritis. Int J Clin Rheumatol 2011;6:273-9
27. Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): A double-blind, randomised controlled trial. Lancet 2008;371:205-14
28. Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: Prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 2010;69:1275-80
29. Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013;72:204-10
30. Alten R. Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis. Expert Rev Clin Immunol 2012;8:123-33
31. Boers M, Buttgereit F. A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. Arthritis Rheum 2011;63(10 Suppl):S359
32. Zakout S, Clark L, Jessop D, et al. Polymyalgia rheumatica has a nocturnal rise in plasma interleukin-6 which is almost completely suppressed by night time administration of modified-release prednisone. Ann Rheum Dis 2012;71:643
33. Alavoine L, Knauer C, Witte S, et al. Chronotherapy with modified release prednisone improves nocturnal asthma [abstract P1173]. Presented at the European Respiratory Society Annual Meeting 2010. p. 205s
34. Buttgereit F, Szechinski J, Doering G, et al. Integrated summary of safety for modified-release prednisone compared to immediate release prednisone: Results from the " ;Circadian Administration of Prednisone in Rheumatoid Arthritis" ; (CAPRA) studies. Ann Rheum Dis 2011;70(Suppl 3):88
35. Alten R, Doering G, Cutolo M, et al. Hypothalamus-pituitary-Adrenal axis function in patients with rheumatoid arthritis treated with night-Time-release prednisone. J Rheumatol 2010;37:2025-31
36. Cutolo M. Chronobiology and the treatment of rheumatoid arthritis. Curr Opin Rheumatol 2012;24:312-18
37. Spies CM, Cutolo M, Straub RH, et al. Prednisone chronotherapy. Clin Exp Rheumatol 2011;29(5 Suppl 68):S42-5
38. Braun T, Schett G. Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep 2012;10:101-8
39. Schoels M, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: Systematic literature review and meta-Analysis informing a consensus statement. Ann Rheum Dis 2013;72:583-9
40. Bijlsma JW. Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology 2012;51:iv9-uv13
41. Buttgereit F. How should impaired morning function in rheumatoid arthritis be treated? Scand J Rheumatol 2011;40(Suppl 125):28-39